The Oncology Pharmacist
  • Home
  • Issues
    • 2023
      • March 2023 - Vol 16 No 2
      • January 2023 - Vol 16 No 1
    • 2022
      • November 2022 - Vol 15 No 6
      • September 2022 - Vol 15 No 5
      • July 2022 - Vol 15 No 4
      • May 2022 - Vol 15 No 3
      • March 2022 - Vol 15 No 2
      • January 2022 - Vol 15 No 1 – Online Only
    • 2021
      • November 2021 - Vol 14 No 7
      • October 2021 - Vol 14 No 6 | Biosimilars
      • September 2021 - Vol 14 No 5
      • July 2021 - Vol 14 No 4
      • May 2021 - Vol 14 No 3
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
        • Checkmate 9LA
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • ASCO 2021 Wrap-Up - Breast Cancer
  • Web Exclusives
    • Ovarian Cancer Overview
    • Interview with the Innovators
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Press Releases
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Author Guidelines
The Oncology Pharmacist

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor, Pharmacy, and Program Director
PGY2, Specialty Residency Hematology/Oncology
University of Kentucky College of Pharmacy, Lexington
Authored Items
Treatment of Advanced Breast Cancer: A Clinical Pharmacy Perspective
Val R. Adams, PharmD, FCCP, BCOP, Allison R. Butts, PharmD, BCOP
Review of Ribociclib for Advanced Hormone Receptor–Positive Breast Cancer in Perspective
Translation of Benchtop Science Arrives in Force, Improves Patient Care
Val R. Adams, PharmD, FCCP, BCOP
2016 First Annual Oncology Guide to New FDA Approvals
Introduction to the Resident Reporter Program
Val R. Adams, PharmD, FCCP, BCOP
Resident Reporter-March 2013 in Supplements
Last modified: March 25, 2020
Latest Issue
 
  • Privacy Policy
  • Terms of Use
  • Home
  • About
  • Subscribe
  • Advertise
  • Contact Us

© Amplity Health. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512

  • Home
  • Issues
    • 2023
      • March 2023 - Vol 16 No 2
      • January 2023 - Vol 16 No 1
    • 2022
      • November 2022 - Vol 15 No 6
      • September 2022 - Vol 15 No 5
      • July 2022 - Vol 15 No 4
      • May 2022 - Vol 15 No 3
      • March 2022 - Vol 15 No 2
      • January 2022 - Vol 15 No 1 – Online Only
    • 2021
      • November 2021 - Vol 14 No 7
      • October 2021 - Vol 14 No 6 | Biosimilars
      • September 2021 - Vol 14 No 5
      • July 2021 - Vol 14 No 4
      • May 2021 - Vol 14 No 3
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
        • Checkmate 9LA
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • ASCO 2021 Wrap-Up - Breast Cancer
  • Web Exclusives
    • Ovarian Cancer Overview
    • Interview with the Innovators
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Press Releases
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Author Guidelines
Sign Up Now!

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive: